HealthyPhase 1NCT02690961
Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers
A Phase 1 study testing Kukoamine B Mesilate in people with Healthy, run by Tianjin Chasesun Pharmaceutical Co., LTD at 1 site in China.
Trial summary
The purpose of this study is to assess safety, tolerance and pharmacokinetics of Multiple-dose Kukoamine B Mesilate in healthy volunteers Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Kukoamine B Mesilate
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteChina
- Study dates
- Mar 2016to 14 Jun 2016
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Gender: male or female, each sex ratio does not exceed 2/3;
- 18-45 years (including upper and lower limit), the general situation is good;
- Body mass index (BMI) in 19-28 (including upper and lower limit of the range), bodyweight（BW）≥ 50kg (female) and 60kg (male);
- Nearly half of the year, no child care program and agreed to take effective measures to contraception during the study period, women of childbearing age blood pregnancy test was negative;
- Subjects to fully understand the purpose, properties, method and reactions may occur of test drug trials.Voluntarily signed the informed consents, and agreed to abide by the requirements of clinical protocols.
Who cannot join
- Primary disease in important organs;
- Mental or physical disability;
- Familial hereditary disease;
- Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood pressure greater than 90-140 millimeters of mercury(mmHg), beyond the scope of 50-90 millimeters of mercury(mmHg), Or pulse (HR) beyond 50bpm-100bpm;
- Abnormal results of any clinically meaningful physical examination, vital signs, ECG or clinical laboratory;
- History of immunodeficiency diseases, including HIV antibody positive;
Show all 15Show fewer
- Detection of antibody positive, hepatitis B surface antigen or antibody to hepatitis C / syphilis positive;
- Alcohol and drug abusers;
- Who is addicted to alcohol and tobacco (drinking 14 units of alcohol per week: 1 unit = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or not smoking and drinking in the test period;
- Any discharge period may affect the study drug, or in the past 3 months participated in any drug clinical trials;
- Before entering the group 4 weeks using any prescription drugs before entering the group, or use of any non prescription drugs within 2 weeks (vitamins, herbal tonics, etc.), or into the group within 2 weeks before taking effect of drug metabolizing enzymes in food, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but must record report in case report form（CRF）;
- The last 3 months had a history of blood donation or significant blood loss (more than 400ml);
- There are drugs, the clinical significance of the history of food allergy and atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug to test drugs or similar drug allergy test;
- Lactating women, pregnant women or unable to take effective contraceptive measures;
- Researchers believe that participants not suitable to take the test for other factors .
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance，Pharmacokinetics of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers
The purpose of this study is to assess safety, tolerance and pharmacokinetics of Multiple-dose Kukoamine B Mesilate in healthy volunteers
- Conditions
- Healthy
- Being tested
- Kukoamine B Mesilate, placebo multiple doses
- Keywords
- Healthy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Kukoamine B MesilateDrug
Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
placebo multiple dosesDrug
| Study group | Role | What they receive |
|---|---|---|
| Kukoamine B Mesilate 0.06mg/kg | Experimental | Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. Receives: Drug: Kukoamine B Mesilate |
| Kukoamine B Mesilate 0.12mg/kg | Experimental | Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. Receives: Drug: Kukoamine B Mesilate |
| Kukoamine B Mesilate 0.24mg/kg | Experimental | Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. Receives: Drug: Kukoamine B Mesilate |
| Placebo 0.06mg/kg | Experimental | Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. Receives: Drug: placebo multiple doses |
| Placebo 0.12mg/kg | Experimental | Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. Receives: Drug: placebo multiple doses |
| Placebo 0.24mg/kg | Experimental | Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. Receives: Drug: placebo multiple doses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse events.
adverse event, physical examination, monitoring of vital signs, Laboratory examination, electrocardiogram(ECG).
Measured: 14 days
Secondary outcomes (1)
Pharmacokinetic parameters(Maximum Plasma Concentration [Cmax])
before the first injecting(omin); after starting the first injecting 30min;ending the first injecting instantly,1h,3h,6h,8h,12h,16h,23h;before the three injections from bottom,after starting the last injecting 30min,ending the last injecting instantly,1h,3h,6h,8h,12h,16h,23h.
Measured: the first day,the sixth day(before the three injections from bottom),the seventh day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2016 (estimated)
- Study startMar 2016
- Primary completion14 Jun 2016
- Study completion14 Jun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tianjin Chasesun Pharmaceutical Co., LTD
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Southwest Hospital, China
- Responsible party
- Sponsor
- Investigators
- Shuai Chen, Study director, Tianjin Chasesun Pharmaceutical Co., LTD
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02690961
- Sponsor's protocol ID
- HR-KB103
- Other IDs
- ChiCTR-TRC-14005111
- Status last verified
- Feb 2016
- First submitted
- 5 Feb 2016
- Last updated
- 3 May 2017
- Results posted
- No
- Data monitoring committee
- No
Publications
Zhao Q, Liu H, Wang Z, Wang T, Cui C, Wang H, Li L, Zhong W, Jiang J, Dong K, Chen S, Jin C, Hu P. Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study. Adv Ther. 2023 Jul;40(7):3186-3198. doi: 10.1007/s12325-023-02521-1. Epub 2023 May 26.
PubMed 37233875
Study at a glance
From the registry record, last updated by the sponsor on 3 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance，Pharmacokinetics of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT02690961
- Acronym / sponsor ID
- HR-KB103
- Conditions
- Healthy
- Keywords
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Tianjin Chasesun Pharmaceutical Co., LTDIndustry (pharma, biotech, devices)
- Collaborators
- Southwest Hospital, China
- Study start
- Mar 2016
- Primary completion
- 14 Jun 2016 (actual)
- Study completion
- 14 Jun 2016 (actual)
- First posted
- 24 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess safety, tolerance and pharmacokinetics of Multiple-dose Kukoamine B Mesilate in healthy volunteers
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Kukoamine B Mesilate 0.06mg/kg | Experimental | Drug: Kukoamine B MesilateDose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. |
| Kukoamine B Mesilate 0.12mg/kg | Experimental | Drug: Kukoamine B MesilateDose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. |
| Kukoamine B Mesilate 0.24mg/kg | Experimental | Drug: Kukoamine B MesilateDose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. |
| Placebo 0.06mg/kg | Experimental | Drug: placebo multiple dosesDose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. |
| Placebo 0.12mg/kg | Experimental | Drug: placebo multiple dosesDose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. |
| Placebo 0.24mg/kg | Experimental | Drug: placebo multiple dosesDose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Gender: male or female, each sex ratio does not exceed 2/3;
- 18-45 years (including upper and lower limit), the general situation is good;
- Body mass index (BMI) in 19-28 (including upper and lower limit of the range), bodyweight（BW）≥ 50kg (female) and 60kg (male);
- Nearly half of the year, no child care program and agreed to take effective measures to contraception during the study period, women of childbearing age blood pregnancy test was negative;
- Subjects to fully understand the purpose, properties, method and reactions may occur of test drug trials.Voluntarily signed the informed consents, and agreed to abide by the requirements of clinical protocols.
Key exclusion criteria (15 listed)
- Primary disease in important organs;
- Mental or physical disability;
- Familial hereditary disease;
- Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood pressure greater than 90-140 millimeters of mercury(mmHg), beyond the scope of 50-90 millimeters of mercury(mmHg), Or pulse (HR) beyond 50bpm-100bpm;
- Abnormal results of any clinically meaningful physical examination, vital signs, ECG or clinical laboratory;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Kukoamine B MesilateKukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers. | Drug | Kukoamine B Mesilate 0.06mg/kg, Kukoamine B Mesilate 0.12mg/kg, Kukoamine B Mesilate 0.24mg/kg |
| placebo multiple doses | Drug | Placebo 0.06mg/kg, Placebo 0.12mg/kg, Placebo 0.24mg/kg |
Primary outcome
Incidence of adverse events.
Time frame: 14 days
adverse event, physical examination, monitoring of vital signs, Laboratory examination, electrocardiogram(ECG).
1 secondary outcome
Pharmacokinetic parameters(Maximum Plasma Concentration [Cmax])
Time frame: the first day,the sixth day(before the three injections from bottom),the seventh day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 May 2017.
- Derived from this study: PubMed 37233875Zhao Q, Liu H, Wang Z, Wang T, Cui C, Wang H, Li L, Zhong W, Jiang J, Dong K, Chen S, Jin C, Hu P. Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study. Adv Ther. 2023 Jul;40(7):3186-3198. doi: 10.1007/s12325-023-02521-1. Epub 2023 May 26.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shuai Chen study director
Tianjin Chasesun Pharmaceutical Co., LTD
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Kukoamine B Mesilate in people with Healthy, run by Tianjin Chasesun Pharmaceutical Co., LTD at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of adverse events. (time frame: 14 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02690961, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2017.